Recently, Prof. Li Tang and Dr. Yugang Guo, founders of Leman Biotech, were invited to Shanghai Pharmaceuticals Group for a visit and exchange. They also visited the Shanghai Biomedical Frontier Industry Innovation Center and the Shanghai Tumor Cellular Therapy Technology Innovation Center, both of which are under construction. Mr. Min Zuo, the former president of Shanghai Pharmaceuticals and chairman of the Shanghai Biomedical Industry Equity Investment Fund, warmly welcomed the Leman Biotech team and participated in a symposium.
During the symposium, Mr. Fei Cheng of the Shanghai Biomedical Industry Equity Investment Fund and Ms. Lin Zhang, Deputy General Manager of the Shanghai Biomedical Frontier Industry Innovation Center, provided insights into the history, development plans, and industry impact of Shanghai Pharmaceuticals, the Shanghai Biomedical Industry Equity Investment Fund, and the Shanghai Biomedical Frontier Industry Innovation Center, leaving a profound impression on the attendees. Prof. Li Tang, co-founder of Leman Biotech, commended the remarkable achievements of Shanghai Pharmaceuticals and the high-quality positioning of the Shanghai Biomedical Frontier Industry Innovation Center.
Subsequently, Dr. Yugang Guo, co-founder of Leman Biotech, introduced Leman Biotech's core technology, Meta 10, to the audience. He presented scientific data on metabolically enhanced immunotherapy technology against T-cell exhaustion in lymphomas and various solid tumors. Prof. Li Tang elaborated on the mechanism of Meta 10, highlighting its ability to effectively enhance the metabolic characteristics of T cells and overcome their exhaustion through metabolic reprogramming. This process promotes the continuous expansion of tumor-specific exhausted T cells in the tumor immune microenvironment while maintaining their killing activity. Consequently, it significantly enhances the therapeutic potential of T cells, ultimately improving the overall clinical response rate and efficacy of T cell therapy.
Dr. Yugang Guo also provided insights into the development of Leman Biotech, particularly the progress of each pipeline and the business model. He shared the latest developments in clinical research, including the successful cure and discharge of the first three patients enrolled in the investigator-initiated clinical study. Mr. Min Zuo of Shanghai Pharmaceuticals expressed his affirmation of Leman Biotech's progress and showed significant interest in the core technology, Meta 10.
Both parties engaged in a warm and in-depth discussion on Meta 10's mechanism, application prospects, intellectual property strategies, and potential cooperation options. Finally, they agreed to hold the next round of seminars to further reach a consensus and explore potential cooperation opportunities.
The Shanghai Biomedical Frontier Industry Innovation Center (SBFIIC) is an innovation and incubation platform led by Shanghai Pharmaceutical Group, in collaboration with the Shanghai Municipal and Pudong New Area governments. The Center is dedicated to establishing a highly integrated innovation incubation platform that brings together government, industry, academia, research, capital, and innovation parks. It aims to provide comprehensive services for biomedical research teams and innovation projects, and to continuously promote the application of cutting-edge technologies in biomedicine and the technology transfer of original innovation project, to facilitate the transformation and industrialization of international cutting-edge technologies and innovative achievements, and to nurture a thriving industrial development ecosystem and contribute to the establishment of a world-class biomedical industry cluster in Shanghai.
